Drug General Information
Drug ID	D0I3YX
Former ID	DNCL001889
Drug Name	Capadenoson
Drug Type	Small molecular drug
Indication	Atrial fibrillation [ICD9: 272, 427.31; ICD10:E78, I48]		Phase 2	[522175]
Company	Bayer HealthCare Pharmaceuticals
Structure		Download 2D MOL 3D MOL
Formula	C25H18ClN5O2S2
PubChem Compound ID	9936489
Target and Pathway
Target(s)	Adenosine A1 receptor	Target Info	Agonist	[529810]
KEGG Pathway	cGMP-PKG signaling pathway
	cAMP signaling pathway
	Sphingolipid signaling pathway
	Neuroactive ligand-receptor interaction
	Morphine addiction
NetPath Pathway	TCR Signaling Pathway
	RANKL Signaling Pathway
PANTHER Pathway	Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
	Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Reactome	Adenosine P1 receptors
	G alpha (i) signalling events
WikiPathways	Nucleotide GPCRs
	GPCRs, Class A Rhodopsin-like
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 522175	ClinicalTrials.gov (NCT00568945) Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.. U.S. National Institutes of Health.
Ref 529810	A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.